Could a Virus Be Responsible for the Rise in Alzheimer’s Cases?

What if the secret to unraveling Alzheimer's disease is not only located in the brain but in a more unexpected source? Scientists have been hunting for the root cause of Alzheimer’s for years without a definitive answer. However, could the solution be lying dormant within viruses that were previously considered harmless? Recent groundbreaking studies are proposing that viruses, such as the cold sore virus (HSV-1), might be playing a significant role in the development of Alzheimer’s. This surprising connection could revolutionize our understanding of the disease and how we can safeguard ourselves.

Overview

• HSV-1, the Cold Sore Virus, Linked to Alzheimer's: Studies have detected HSV-1 in the brains of older individuals, and in conjunction with specific genetic factors, it may substantially elevate the risk of Alzheimer’s.

• Shingles Virus May Reactivate Dormant HSV-1: Brain cells infected with HSV-1 exhibit increased inflammation and protein accumulation, but it's the reactivation of HSV-1 (such as during a shingles infection) that significantly escalates the Alzheimer's-like damage.

• Antiviral Drugs and Vaccines Offer Hope: Treatments with antiviral medications and the Shingrix vaccine could potentially prevent or lessen Alzheimer's damage by targeting the reactivation of HSV-1, providing a potential avenue to delay or prevent the disease.

New Research Suggests Shingles Virus Could Fuel Alzheimer's – Here’s How

What initiates the progression leading to Alzheimer’s? Despite decades of research, a definitive answer has remained elusive. One area that has received minimal attention is the potential impact of viruses.

Increasing evidence points towards HSV-1, the cold sore virus, as a primary suspect. However, it doesn't act alone. Let’s explore recent scientific findings and their implications for you and actionable steps you can take...

Substantial scientific evidence implicates infectious agents in the progression of Alzheimer’s, yet securing funding for this research field has been challenging.

Researchers tend to gravitate towards areas with ample research funding. This is where the spotlight shines, and for Alzheimer’s disease, that focus has been on amyloid plaque research. Those delving into less financially lucrative or career-advancing research areas typically receive minimal attention.

For instance, molecular virologist Ruth Itzhaki, a pioneer in viral research, faced resistance and indifference towards her work, stating, "Hostility or derision occurred with most of my papers on the topic, and many people simply ignored them."

Despite these challenges, Professor Itzhaki and her team at the University of Oxford persist. Recently, she collaborated with researchers at Tufts University in Greater Boston to produce more groundbreaking studies.

Cold Sore Virus Implicated

Prof. Itzhaki had previously concentrated on the possible role of herpes simplex virus type 1 (HSV-1), the strain responsible for cold sores. It is estimated that half the global population under 50 years old has encountered HSV-1. While it typically remains dormant in nerve cells, stress and compromised immune systems can reactivate it.

Given the prevalent stress and suboptimal immune systems in today's society due to toxins and poor diets, a considerable number of individuals could be at risk for Alzheimer’s.

Over the past three decades, Prof. Itzhaki’s team has demonstrated the presence of HSV-1 DNA in the brains of a significant proportion of elderly individuals. Furthermore, they found that when the virus is present in the brain alongside a specific genetic factor, it substantially raises the risk of developing Alzheimer’s. Additionally, there are notable correlations between the virus's effects and the disease's characteristic features.

Encouragingly, Prof. Itzhaki and her team have uncovered that treating lab-grown HSV-1-infected cells with antiviral agents shields against Alzheimer’s.

Virus Triggers the Accumulation of Amyloid Plaque

Support for this notion comes from Tufts University. Their research showed that virus activation leads to neuroinflammation, accumulation of amyloid beta and tau proteins, and neuronal function loss – all hallmarks found in Alzheimer’s patients.

David Kaplan, Stern Family Professor of Engineering at Tufts, remarked, “We have been building upon well-established evidence linking HSV to an increased risk of Alzheimer’s disease in patients.”

A One-Two Infectious Punch

In a recent study published in the Journal of Alzheimer's Disease in August, Prof. Itzhaki, Prof. Kaplan, and Dana Cairns from Tufts delved into varicella zoster virus (VZV), another type of herpes virus causing chickenpox and shingles.

Utilizing lab-grown brain cells and a 3D bioengineered brain-like tissue model, they observed that VZV infection didn’t induce amyloid clusters or tau tangles. However, they did witness gliosis - a response in glial cells to the infection resulting in scarring - and an upsurge in inflammatory cytokines. What does this signify? Their findings imply that while VZV may harm the brain, it's unlikely to be a direct cause of Alzheimer’s.

Nevertheless, when infecting cells harboring latent HSV-1, the virus reactivated, leading to a substantial rise in amyloid and tau levels. This indicates that severe VZV infections in humans, such as shingles, could reactivate latent HSV-1 in the brain, potentially resulting in Alzheimer’s-like damage.

Prof. Itzhaki elucidated, stating, “This striking outcome appears to confirm that in humans, infections like VZV can induce increased brain inflammation, potentially reactivating dormant HSV-1.

“The cumulative brain damage from recurrent infections throughout one's life would eventually culminate in Alzheimer’s dementia.”

Dana Cairns concurs. “It’s a dual attack of two commonly harmless viruses, but laboratory studies suggest that if exposure to VZV awakens dormant HSV-1, complications could arise.”

What Can You Do?

The positive news is that evidence indicates antiviral medications can shield against damage from these infectious agents. Furthermore, researchers recommend individuals over 50 to receive the shingles vaccine to prevent infection occurrence. Even if you've experienced shingles, getting vaccinated with Shingrix is advised.

Shingrix is a non-live vaccine containing a virus component. It is administered in two doses, spaced apart by two to six months.

Summary

Recent research indicates that herpes simplex virus type 1 (HSV-1) could play a pivotal role in Alzheimer’s disease development. The combination of HSV-1 and specific genetic factors has been shown to heighten the risk of Alzheimer’s, resulting in neuroinflammation and amyloid plaque accumulation in the brain. Recent studies also suggest that the shingles virus (VZV) could reactivate latent HSV-1, exacerbating damage. However, antiviral treatments and vaccines like Shingrix offer hope in preventing or mitigating this damage, particularly for individuals over 50.

Frequently Asked Questions

What is the connection between HSV-1 and Alzheimer's?

Can shingles cause Alzheimer's?

Shingles (caused by VZV) can reactivate latent HSV-1 in the brain, potentially leading to Alzheimer’s-like damage.

How can I protect myself from the risks associated with HSV-1?

Using antiviral medications and receiving the shingles vaccine (Shingrix) can help prevent HSV-1 reactivation and the potential onset of Alzheimer’s.

Why hasn’t the link between viruses and Alzheimer’s been widely studied before?

Research in this field has been limited due to funding constraints and a predominant focus on amyloid plaque research, with scientists more inclined towards pursuing better-funded avenues.

Should I get the Shingrix vaccine if I’ve already had shingles?

Absolutely, even if you've experienced shingles, obtaining the Shingrix vaccine can assist in averting future outbreaks and potential Alzheimer’s risks associated with HSV-1 reactivation.